Rein Therapeutics (RNTX) Goodwill & Intangibles (2023 - 2026)

Rein Therapeutics (RNTX) has reported Goodwill & Intangibles for 4 consecutive years, with $19.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill & Intangibles fell 59.14% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $19.8 million (down 59.14% YoY), while the FY2025 annual figure was $19.8 million, down 59.14% from the prior year.
• Goodwill & Intangibles held at $19.8 million in Q1 2026 per RNTX's latest filing, from $19.8 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $85.5 million in Q4 2023 and bottomed at $19.8 million in Q4 2025.
• Historically, Goodwill & Intangibles has averaged $57.6 million across 4 years, with a median of $48.5 million in 2024.
• Annual changes were most pronounced in 2024 — Goodwill & Intangibles tumbled 43.26% — and 2025, when it slumped 59.14%.
• Rein Therapeutics' Goodwill & Intangibles stood at $85.5 million in 2023, then sank by 43.26% to $48.5 million in 2024, then plunged by 59.14% to $19.8 million in 2025, then changed by 0.0% to $19.8 million in 2026.
• Business Quant data shows RNTX's Goodwill & Intangibles at $19.8 million in Q1 2026, $19.8 million in Q4 2025, and $48.5 million in Q3 2025.